Leveraging Computational Approaches in Antibody Workflows: Discovery, Design and Engineering
September 17, 2019 | Discovery on target
Leveraging Computational Approaches in Antibody Workflows: Discovery, Design and Engineering
A Global Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety And Efficacy Of Vis410 In Combination With Oseltamivir Versus Oseltamivir Alone In Hospitalized Adults With Influenza A Requiring Oxygen
August 28, 2019 | International Society for Influenza and Respiratory Viruses (ISIRV) 'OPTIONS X' Conference
A Global Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety And Efficacy Of Vis410 In Combination With Oseltamivir Versus Oseltamivir Alone In Hospitalized Adults With Influenza A Requiring Oxygen
VIS410, A Broad-Spectrum Anti-Influenza A Monoclonal Antibody Neutralized Baloxovir Resistant Influenza A Virus In-Vitro
August 28, 2019 | International Society for Influenza and Respiratory Viruses (ISIRV) 'OPTIONS X' Conference
VIS410, A Broad-Spectrum Anti-Influenza A Monoclonal Antibody Neutralized Baloxovir Resistant Influenza A Virus In-Vitro
Designing and Engineering Antibodies to Mutable Protein Targets
April 14, 2019 | World Vaccine Congress
Designing and Engineering Antibodies to Mutable Protein Targets
Pharmacophore-based Protein Surface Patch Searching and Its Application to in silico Antibody Engineering
April 11, 2019 | PEGS
Pharmacophore-based Protein Surface Patch Searching and Its Application to in silico Antibody Engineering
Antibody Design and Engineering Through Integration of Computational and Experimental Methods
February 26, 2019 | Antibody Engineering & Therapeutics, Asia
Antibody Design and Engineering Through Integration of Computational and Experimental Methods
Improved Computational Modeling of Antibody-Antigen Complexes by Integration of Deep Mutational Scanning Data
January 15, 2019 | Peptalk
Improved Computational Modeling of Antibody-Antigen Complexes by Integration of Deep Mutational Scanning Data
Structure Guided Optimization of Antibody Fc and Fab Domains for Improved Pharmacokinetic Properties
January 15, 2019 | Peptalk
Structure Guided Optimization of Antibody Fc and Fab Domains for Improved Pharmacokinetic Properties
(Sibeprenlimab), an APRIL-Neutralizing IgG2
November 13, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
(Sibeprenlimab), an APRIL-Neutralizing IgG2
Monoclonal Antibody, in Healthy Volunteers
November 13, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
